-+ 0.00%
-+ 0.00%
-+ 0.00%

BeOne Medicines publishes 2025 Responsible Business and Sustainability Report

PUBT·04/14/2026 13:07:15
Listen to the news
BeOne Medicines publishes 2025 Responsible Business and Sustainability Report
  • BeOne Medicines outlined sustainability priorities alongside FY25 growth, reporting USD 5.3 billion product revenue, up 40% year over year.
  • Scope 1 and 2 greenhouse-gas emissions intensity fell 25% per unit of internally manufactured commercial product, meeting 2026 target in October 2025.
  • Climate plan reset to a 50% Scope 1 and 2 emissions-intensity reduction by 2030 from a 2024 baseline.
  • First quantitative Scope 3 target set, aiming for a 10% emissions-intensity reduction by 2030 from a 2024 baseline.
  • Operational scale-up continued, with medicines authorized in more than 75 markets, supported by about 12,000 colleagues.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260414-12105505), on April 14, 2026, and is solely responsible for the information contained therein.